Xintela AB (publ) (STO:XINT)

Market Cap	175.70M -44.7%
Revenue (ttm)	2.59M -36.3%
Net Income	-49.92M
EPS	-0.08
Shares Out	861.27M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	230,679
Open	0.2030
Previous Close	0.2010
Day's Range	0.1990 - 0.2080
52-Week Range	0.1610 - 0.5340
Beta	2.02
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 28, 2026

About Xintela AB

Xintela AB (publ), a biopharma company, develops medical products in the field of stem cell therapy and targeted cancer therapy. The company’s stem cell products include XSTEM, which is in Phase I/IIa clinical development for the treatment of knee osteoarthritis, as well as in clinical study for the treatment of difficult-to-heal leg ulcers, acute respiratory distress syndrome; and EQSTEM that is in preclinical development for the treatment of joint disease in horses. It is also developing antibody-based cancer therapies, such as TARG9 and TARG...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2009
• Employees: 11
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: XINT

Financial Performance

In 2025, Xintela AB's revenue was 2.28 million, a decrease of -45.86% compared to the previous year's 4.22 million. Losses were -48.56 million, 23.9% more than in 2024.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jul 3, 2026

Data Sources Report a data error